Balchem Co. (NASDAQ:BCPC) Shares Sold by Profund Advisors LLC

Profund Advisors LLC decreased its holdings in Balchem Co. (NASDAQ:BCPC) by 8.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,644 shares of the basic materials company’s stock after selling 155 shares during the quarter. Profund Advisors LLC’s holdings in Balchem were worth $253,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Bessemer Group Inc. grew its position in Balchem by 568.9% in the first quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company’s stock worth $47,000 after buying an additional 256 shares during the last quarter. YHB Investment Advisors Inc. purchased a new position in Balchem during the 1st quarter worth approximately $69,000. GAMMA Investing LLC grew its position in Balchem by 18.0% during the 1st quarter. GAMMA Investing LLC now owns 473 shares of the basic materials company’s stock worth $73,000 after purchasing an additional 72 shares in the last quarter. TD Asset Management Inc purchased a new position in Balchem during the 2nd quarter worth approximately $200,000. Finally, Heritage Family Offices LLP purchased a new position in Balchem during the 2nd quarter worth approximately $206,000. Institutional investors and hedge funds own 87.91% of the company’s stock.

Balchem Trading Down 0.0 %

Shares of NASDAQ:BCPC opened at $175.13 on Friday. The firm has a fifty day moving average of $171.68 and a two-hundred day moving average of $159.94. The firm has a market capitalization of $5.68 billion, a P/E ratio of 49.47, a price-to-earnings-growth ratio of 5.54 and a beta of 0.65. Balchem Co. has a 12-month low of $110.74 and a 12-month high of $186.03. The company has a quick ratio of 1.79, a current ratio of 2.83 and a debt-to-equity ratio of 0.26.

Balchem (NASDAQ:BCPC) last issued its earnings results on Friday, July 26th. The basic materials company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. The company had revenue of $234.08 million during the quarter, compared to analyst estimates of $241.26 million. Balchem had a net margin of 12.52% and a return on equity of 10.94%. On average, equities analysts expect that Balchem Co. will post 3.96 EPS for the current fiscal year.

Insider Buying and Selling at Balchem

In other Balchem news, SVP Gunsteren Job Leonard Van sold 7,750 shares of Balchem stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $180.05, for a total transaction of $1,395,387.50. Following the completion of the sale, the senior vice president now owns 8,540 shares of the company’s stock, valued at approximately $1,537,627. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.25% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. HC Wainwright lifted their price objective on shares of Balchem from $170.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. StockNews.com cut shares of Balchem from a “buy” rating to a “hold” rating in a research report on Monday, July 29th.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.